Opinion|Videos|July 4, 2024
Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.
Advertisement
Episodes in this series
- In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
Photobiomodulation, Bio-Machines, and the Future of Dermatology
3
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
4
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
5
